Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21799578 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL8553937 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL9322416 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL5839696 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL491616 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL491983 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL21799504 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL21799790 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL10480715 | 0.98 | HRH3 (0.71) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| Hydrazine SCHEMBL8558416 | 0.98 | HRH3 (0.71) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121735844-B | Cathode interface material and preparation method and application thereof | 江汉大学 | 2026-05-19 | — | — | CN | claimed |
| CN-103123672-A | Target gene Rv0233 screened by antituberculous inhibitor and application | UNIV HUAZHONG AGRICULTURAL | 2013-05-29 | — | — | CN | claimed |
| CN-103122364-A | Antitubercular inhibitor screened target gene Rv2498c and application thereof | UNIV HUAZHONG AGRICULTURAL | 2013-05-29 | — | — | CN | claimed |
| CN-121735844-B | Cathode interface material and preparation method and application thereof | 江汉大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-02-15 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20200199282-A1 | Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-06-25 | — | — | US | disclosed |
| EP-0310321-A2 | Immunomodulatory azaspiranes | SMITHKLINE BEECHAM CORPORATION (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4585869-A | ANTIINFLAMMATORY, ANALGESIC, ANTIULCER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-04-29 | — | — | US | disclosed |
| US-4549023-A | ANTINFLAMMATORY AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0049779-B1 | 3-AMINOINDAZOLE DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4474964-A | 3-Aminoindazole derivatives | ASAHI, KASEI, KOGYO, KABUSHIKI, KAISHA (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0049779-A1 | 3-Aminoindazole derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-04-21 | — | — | EP | disclosed |
| US-4306063-A | 4-Substituted 3,5-morpholinediones | MCNEIL LABORATORIES, INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4256891-A | (2-Amino-2-oxoethoxy)acetic acid compounds | MCNEIL LABORATORIES, INC. (US) | 1981-03-17 | — | — | US | disclosed |
| US-3995045-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | HRH3 2171/4885SMN1; SMN2 2768/4885KEAP1 4175/4885 |
| US-20240051946-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | HRH3 3114/4885SMN1; SMN2 3615/4885KEAP1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.